Regal Investment Advisors LLC Grows Stock Holdings in Royalty Pharma PLC $RPRX

Regal Investment Advisors LLC increased its position in Royalty Pharma PLC (NASDAQ:RPRX) by 18.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 109,724 shares of the biopharmaceutical company’s stock after buying an additional 16,792 shares during the period. Regal Investment Advisors LLC’s holdings in Royalty Pharma were worth $3,871,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Smartleaf Asset Management LLC raised its holdings in Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 790 shares during the period. Financial Consulate Inc. bought a new position in shares of Royalty Pharma in the third quarter worth about $35,000. Richardson Financial Services Inc. purchased a new stake in shares of Royalty Pharma during the third quarter worth about $54,000. Farther Finance Advisors LLC grew its position in shares of Royalty Pharma by 44.3% during the third quarter. Farther Finance Advisors LLC now owns 2,060 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 632 shares in the last quarter. Finally, Fifth Third Bancorp raised its stake in Royalty Pharma by 16.9% during the 3rd quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 362 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Marshall Urist sold 20,000 shares of the stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $40.26, for a total value of $805,200.00. Following the completion of the transaction, the executive vice president owned 20,000 shares of the company’s stock, valued at approximately $805,200. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Terrance P. Coyne sold 114,954 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the completion of the transaction, the chief financial officer directly owned 23,972 shares of the company’s stock, valued at approximately $1,026,960.48. The trade was a 82.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 737,078 shares of company stock valued at $29,862,002 in the last three months. Corporate insiders own 18.90% of the company’s stock.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of research analyst reports. Leerink Partners set a $45.00 price target on Royalty Pharma in a report on Thursday, December 11th. TD Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Wall Street Zen cut shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Morgan Stanley reissued an “overweight” rating and issued a $61.00 target price on shares of Royalty Pharma in a report on Thursday, February 12th. Finally, Citigroup upped their target price on shares of Royalty Pharma from $48.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $48.67.

Royalty Pharma Stock Down 0.5%

Shares of RPRX opened at $45.65 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.40 and a quick ratio of 2.40. The stock has a market capitalization of $26.33 billion, a price-to-earnings ratio of 33.81 and a beta of 0.40. Royalty Pharma PLC has a 1 year low of $29.66 and a 1 year high of $47.86. The business’s 50 day simple moving average is $43.25 and its 200-day simple moving average is $39.54.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The firm had revenue of $621.99 million during the quarter, compared to analyst estimates of $839.97 million. As a group, equities analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th were paid a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Friday, February 20th. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio is 69.63%.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.